Personalized Medicine and Other Emerging Therapy in Hematologic Malignancies

A special issue of Journal of Personalized Medicine (ISSN 2075-4426). This special issue belongs to the section "Personalized Therapy and Drug Delivery".

Deadline for manuscript submissions: closed (15 May 2024) | Viewed by 160

Special Issue Editor

E-Mail Website
Guest Editor
Department of Head and Neck Oncology, Gustave Roussy Cancer Campus, Villejuif, France
Interests: haematology; oncology; descriptive studies; Middle East; epidemiologic studies; cohort studies; clinical studies; middle east studies; observational studies

Special Issue Information

Dear Colleagues,

Hematologic malignancies are cancers that originate in hematopoietic tissues (such as bone marrow) or cells of the immune system. There are three main types of hematological malignancies: leukemia, lymphoma, and multiple myeloma. There are increasing reports that hematological malignancies, such as leukemia and lymphoma, afflict millions of adults and children every year, and are often deadly. Therefore, it is increasingly urgent to explore emerging therapy methods to treat hematologic malignancies.

This Special Issue will focus a broad range of innovative treatments, including bispecific antibodies, new monoclonal antibodies, CAR-T cells, small molecules in targeted cancer therapy, immunoconjugates, targeted drugs, immunotherapy, tyrosine kinase inhibitors, amongst others.

This Special Issue aims to provide a discussion platform for the diagnosis and treatment of hematological malignancies in personalized medicine and to promote academic exchanges and experience sharing of personalized medicine in hematological malignancies. In this Special Issue, we aim to focus on personalized medicine for hematologic malignancies; original research articles, review articles, etc., are welcome.

Dr. Khalil Saleh
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Personalized Medicine is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


  • hematologic malignancies
  • CAR-T cells
  • targeted cancer therapy
  • personalized medicine
  • immunotherapy
  • bispecific antibodies

Published Papers

There is no accepted submissions to this special issue at this moment.
Back to TopTop